What Is Dulaglutide? A Complete Guide to Uses, Dosage, and Side Effects

Dulaglutide comes as a pre-filled, single-dose pen containing 0.5 mL of clear, colorless solution. It is injected once a week under the skin (subcutaneously). It is not injected into a muscle or vein.<\/p>

The Standard Dose Escalation Schedule<\/strong><\/h3>

Your doctor will typically start at the lowest dose and increase gradually. This step-up approach is specifically designed to reduce GI side effects while your body adapts.<\/p>

Stage<\/strong><\/th>	Dose<\/strong><\/th>	Purpose<\/strong><\/th><\/tr><\/thead>
Weeks 1 to 4<\/td>	0.75 mg once weekly<\/td>	Starting dose: establish GI tolerance<\/td><\/tr>
Week 5 onward<\/td>	1.5 mg once weekly<\/td>	Standard maintenance dose for most patients<\/td><\/tr>
If additional control needed (minimum 4-week intervals)<\/td>	3.0 mg once weekly<\/td>	Dose escalation step<\/td><\/tr>
Maximum approved dose<\/td>	4.5 mg once weekly<\/td>	Approved since 2020 for patients requiring further glycemic control<\/td><\/tr><\/tbody><\/table><\/figure> Per the FDA prescribing information<\/a>, the maximum approved dose is 4.5 mg once weekly<\/strong>. Dose changes should occur at intervals of at least 4 weeks<\/strong>.<\/p> How to Inject Dulaglutide Correctly<\/strong><\/h3> Inject into the abdomen, thigh, or upper arm<\/strong> subcutaneously (under the skin).<\/li> Rotate the injection site with each dose to reduce the chance of skin irritation.<\/li> The injection may be taken with or without food, at any time of day.<\/li> Aim to use it on the same day each week for consistency.<\/li> Allow the pen to reach room temperature before injecting.<\/li> Do not<\/strong> mix dulaglutide with insulin in the same syringe. They may be used in the same body area, but not at adjacent spots.<\/li> Never share your pen with another person.<\/li> Store in the refrigerator (2 degrees C to 8 degrees C<\/strong>). The pen may be kept at room temperature for up to 14 days<\/strong> if temporary refrigeration is unavailable. Never freeze it.<\/li> <\/ul> If you miss a dose, use it as soon as you remember. If your next scheduled dose is 3 or fewer days away, skip the missed dose and resume your regular schedule. Never take a double dose.<\/p> Always follow the specific instructions provided by your doctor or pharmacist. The above is general guidance only.<\/p> 6. Dulaglutide Side Effects: Common and Serious<\/strong><\/h2> Like all prescription medications, dulaglutide may cause side effects. The majority are gastrointestinal and tend to be mild to moderate, particularly during the first weeks.<\/p> Common Side Effects (Affecting More Than 1 in 10 People)<\/strong><\/h3> Based on clinical trial data cited in the FDA label<\/a>:<\/p> Side Effect<\/strong><\/th> Reported Frequency<\/strong><\/th> When It Typically Occurs<\/strong><\/th><\/tr><\/thead> Nausea<\/td> Up to 21.1%<\/td> First 2 to 3 days after initial dose or after a dose increase; usually eases within 2 weeks<\/td><\/tr> Diarrhea<\/td> Up to 13.7%<\/td> Early weeks of treatment<\/td><\/tr> Vomiting<\/td> Up to 11.5%<\/td> Early weeks; more frequent at higher doses<\/td><\/tr> Abdominal pain<\/td> 1% to 10%<\/td> Throughout treatment; usually mild<\/td><\/tr> Decreased appetite<\/td> 1% to 10%<\/td> Common; contributes to modest weight reduction<\/td><\/tr> Indigestion \/ GERD<\/td> 1% to 10%<\/td> Ongoing; related to slower gastric emptying<\/td><\/tr> Fatigue<\/td> 1% to 10%<\/td> Primarily in early weeks<\/td><\/tr><\/tbody><\/table><\/figure> GI side effects are dose-dependent and tend to ease as the body adjusts. Eating smaller, lower-fat meals, staying well hydrated, and avoiding lying down after eating may help manage these effects in the early weeks.<\/p> Serious Side Effects That Require Immediate Attention<\/strong><\/h3> While uncommon, the following require prompt medical evaluation:<\/p> Pancreatitis: <\/strong>Sudden, severe abdominal or back pain, sometimes with nausea or vomiting. During clinical trials, 5 confirmed cases<\/strong> of pancreatitis were reported in dulaglutide-exposed patients versus 1 in the comparator group. Discontinue the medication and seek medical care if pancreatitis is suspected.<\/li> Thyroid tumor risk (boxed warning): <\/strong>Dulaglutide caused thyroid C-cell tumors in rodent studies. Human relevance is not established, but contact your doctor if you notice a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath. Dulaglutide is contraindicated<\/strong> in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<\/li> Acute kidney injury: <\/strong>Primarily reported in patients who became severely dehydrated from vomiting or diarrhea. Drink adequate fluids, especially during the first weeks of treatment.<\/li> Hypoglycemia: <\/strong>Dulaglutide alone carries a low hypoglycemia risk. That risk increases when combined with insulin or sulfonylureas. Symptoms include shakiness, sweating, confusion, and rapid heartbeat.<\/li> Gallbladder disease: <\/strong>GLP-1 receptor agonists as a class may increase the risk of gallbladder events. Report persistent upper-right abdominal pain, fever, or jaundice to your doctor.<\/li> Serious allergic reactions: <\/strong>Rare but possible. Seek emergency care immediately if you develop hives, facial or throat swelling, or difficulty breathing.<\/li> <\/ul> This is not an exhaustive list. Please refer to the full prescribing information or discuss all potential side effects with your doctor or pharmacist.<\/em><\/td><\/tr><\/tbody><\/table><\/figure> 7. Who Should and Should Not Take Dulaglutide?<\/strong><\/h2> Not every person with type 2 diabetes is a suitable candidate. Your doctor will evaluate your full medical history before prescribing.<\/p> Who May Benefit Most<\/strong><\/h3> Adults and children aged 10 and older with type 2 diabetes who need better blood sugar control alongside diet and exercise.<\/li> Patients with type 2 diabetes who also have established cardiovascular disease or multiple cardiovascular risk factors.<\/li> Patients with chronic kidney disease:<\/strong> dulaglutide does not require renal dose adjustments and may offer kidney-protective benefits based on REWIND renal data.<\/li> Those who prefer a convenient once-weekly injection over daily injections or additional oral tablets.<\/li> <\/ul> Who Should Not Take Dulaglutide<\/strong><\/h3> Contraindication or Caution<\/strong><\/th> Reason<\/strong><\/th><\/tr><\/thead> Personal or family history of medullary thyroid carcinoma (MTC)<\/td> Boxed warning: potential thyroid C-cell tumor risk<\/td><\/tr> Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)<\/td> Boxed warning<\/td><\/tr> Serious hypersensitivity to dulaglutide or its components<\/td> Risk of anaphylaxis or serious allergic reaction<\/td><\/tr> Type 1 diabetes<\/td> Not approved; does not address the underlying mechanism of type 1 diabetes<\/td><\/tr> Diabetic ketoacidosis (DKA)<\/td> Not indicated for DKA treatment<\/td><\/tr> History of pancreatitis<\/td> Use with caution; discontinue immediately if pancreatitis occurs<\/td><\/tr> Severe gastroparesis<\/td> Dulaglutide further slows gastric emptying<\/td><\/tr> Pregnancy and breastfeeding<\/td> Safety not established; discuss with your doctor<\/td><\/tr><\/tbody><\/table><\/figure> Talk with your doctor about all medications, supplements, and herbal products you take. Dulaglutide may affect the absorption of other oral medications due to its effect on gastric emptying.<\/p> 8. Dulaglutide and Weight Loss: What to Realistically Expect<\/strong><\/h2> This is among the most frequently asked questions about dulaglutide, particularly given the current interest in GLP-1 medications for weight management.<\/p> The direct answer: dulaglutide is not approved<\/strong> as a weight loss medication. However, it may produce modest weight reduction as a secondary effect due to slowed gastric emptying and reduced appetite.<\/p> In the AWARD-11 trial<\/em>, weight reductions at 36 weeks<\/strong> were dose-dependent: patients on 1.5 mg lost approximately 3.1 kg<\/strong>, those on 3.0 mg lost approximately 4.0 kg<\/strong>, and those on 4.5 mg lost approximately 4.7 kg<\/strong> on average. <\/p> Overall, most published data suggest weight reductions in the range of 3 to 5% of body weight<\/strong> in clinical trial settings.<\/p> This is considerably more modest than what is typically observed with higher-dose semaglutide formulations (Ozempic<\/a> at therapeutic doses, or Wegovy<\/a>), which can produce weight reductions of 10 to 15%+<\/strong> in clinical trials. <\/p> For patients whose primary goal is significant weight loss, this distinction is clinically important, and a doctor may recommend a dedicated GLP-1 weight loss program<\/a> or alternative medication approved specifically for that purpose.<\/p> For patients using dulaglutide to manage type 2 diabetes and associated metabolic risk, even modest weight reductions can meaningfully improve blood sugar control, blood pressure, and cardiovascular outcomes. Any changes in weight should be discussed within the context of your overall health goals.<\/p> The Bottom Line<\/strong><\/h2> Dulaglutide (Trulicity) is a well-studied, once-weekly injectable GLP-1 receptor agonist with strong clinical evidence behind it. In the AWARD trial program<\/em>, it reduced HbA1c by up to 1.9%<\/strong>. In the landmark REWIND trial<\/em>, it lowered the risk of major cardiac events by 12%<\/strong> and reduced composite renal outcomes by 15%<\/strong> over more than 5 years of follow-up.<\/p> Most side effects are GI-related and ease within the first few weeks. Serious side effects are uncommon but recognizable, and prompt medical attention makes all the difference.<\/p> Dulaglutide is a prescription-only medication, and the right dose and treatment approach depend entirely on your individual health profile. Always work with your endocrinologist, diabetologist, or primary care physician to determine whether it is appropriate for you.<\/p> Frequently Asked Questions About Dulaglutide<\/strong><\/h2> Is dulaglutide the same as insulin?<\/strong><\/h3> No. Dulaglutide is not<\/strong> insulin. It is a GLP-1 receptor agonist that works by stimulating the body’s own pancreas to release insulin in response to elevated blood glucose. <\/p> Unlike insulin, it does not directly introduce insulin into the body, and it carries a substantially lower risk of hypoglycemia when used on its own. <\/p> Some patients may use both dulaglutide and insulin simultaneously, as prescribed by their doctor.<\/p> What is dulaglutide made of, and how is it produced?<\/strong><\/h3> Dulaglutide is a biosynthetic fusion protein<\/strong>. It consists of two identical GLP-1 analogue chains, each linked to a modified human IgG4 antibody fragment. <\/p> According to the FDA prescribing information<\/a>, it has 90% amino acid sequence homology to endogenous human GLP-1 and is produced using mammalian cell cultures through recombinant DNA technology. <\/p> Each 0.5 mL pen contains dulaglutide along with citric acid, mannitol, polysorbate 80, and trisodium citrate dihydrate in water for injection.<\/p> Can dulaglutide be used for weight loss in India?<\/strong><\/h3> Dulaglutide is not approved<\/strong> as a weight loss medication in India or globally. Modest weight reduction, typically 3 to 5% of body weight<\/strong>, may occur as a secondary effect in patients using it for type 2 diabetes management. <\/p> If weight management is your primary treatment goal, discuss dedicated options with your doctor — including those in the MetaGo weight loss program<\/a> — as other GLP-1 medications have stronger evidence and regulatory approval specifically for weight management.<\/p> What is the difference between dulaglutide (Trulicity) and semaglutide (Ozempic)?<\/strong><\/h3> Both are GLP-1 receptor agonists, but they differ in molecular structure, available doses, and clinical outcomes. Semaglutide at higher approved doses tends to produce greater HbA1c reductions and significantly more weight loss. <\/p> Dulaglutide has particularly robust cardiovascular outcome data from the REWIND trial<\/em>, including benefits in primary cardiovascular prevention. <\/p> The right choice depends on your individual health profile, coexisting conditions, and treatment goals. For a detailed head-to-head comparison, see our semaglutide vs dulaglutide guide<\/a>. Your doctor is best placed to advise which is more appropriate for you.<\/p> How long does dulaglutide take to show results?<\/strong><\/h3> Most patients see meaningful improvements in fasting blood glucose within the first 2 to 4 weeks<\/strong>. HbA1c reductions become measurable at the first routine follow-up, typically after 12 weeks<\/strong>. <\/p> Full benefits at a given dose generally stabilize over 3 to 6 months<\/strong>. GI side effects, if present, usually improve considerably after the first 2 weeks<\/strong>.<\/p> <\/p> Source Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-130. https://www.thelancet.com/journalslancet/article/PIIS0140-6736(19)31150-X/abstract Gerstein HC, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. 2019. https://pubmed.ncbi.nlm.nih.gov/31189509/ Frias JP, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes (AWARD-11). Diabetes Care. 2021;44(3):765-773. https://diabetesjournals.org/care/article/44/3/765/138650 Trulicity (dulaglutide) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf Trulicity (dulaglutide) DailyMed Label. National Library of Medicine (NIH). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309 Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection. PMC (NCBI). 2015. PMC4665063. https://pmc.ncbi.nlm.nih.gov/articles/PMC4665063/ Glycaemic efficacy of expanded dose range of dulaglutide by baseline HbA1c: Post hoc analysis of AWARD-11. PMC (NCBI). 2021. PMC9292947. https://pmc.ncbi.nlm.nih.gov/articles/PMC9292947/ Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. PubMed (NCBI). 2021. https://pubmed.ncbi.nlm.nih.gov/34189841/ Dulaglutide side effects data. Drugs.com clinical reference. https://www.drugs.com/sfx/dulaglutide-side-effects.html Dulaglutide (subcutaneous route) prescribing and dosage information. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/dulaglutide-subcutaneous-route/description/drg-20122526 Dr. Abhinav Garg MBBS, MD (Internal Medicine), [Expert Doctor, 10+ years of experience in obesity care Treated 240+ patients with GLP-1 medications]